CN Patent

CN109496151A — 用于治疗疼痛的塞来昔布口服组合物

Assigned to Dr Reddys Laboratories Ltd · Expires 2019-03-19 · 7y expired

What this patent protects

本发明涉及塞来昔布或其药学上可接受的盐的稳定的口服液体药物组合物。在以50rpm的速度搅拌下经受pH为2.0、温度为37℃±0.5℃的禁食状态模拟胃液(FaSSGF)时，存在于如本文所述的组合物中的塞来昔布至少60分钟不显示任何沉淀。本申请还涉及制备所述塞来昔布组合物的方法和使用所述塞来昔布组合物的方法。

USPTO Abstract

本发明涉及塞来昔布或其药学上可接受的盐的稳定的口服液体药物组合物。在以50rpm的速度搅拌下经受pH为2.0、温度为37℃±0.5℃的禁食状态模拟胃液(FaSSGF)时，存在于如本文所述的组合物中的塞来昔布至少60分钟不显示任何沉淀。本申请还涉及制备所述塞来昔布组合物的方法和使用所述塞来昔布组合物的方法。

Drugs covered by this patent

Celebrex (celecoxib) · Pfizer Inc. (originally Searle/Pharmacia)

Patent Metadata

Patent number: CN109496151A
Jurisdiction: CN
Classification: —
Expires: 2019-03-19
Drug substance claim: No
Drug product claim: No
Assignee: Dr Reddys Laboratories Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.